bioMérieux announces a joint initiative with Mérieux NutriSciences, called 'Trusted Third Party', to launch a new collaborative, data-driven model to improve food safety monitoring systems.
This model has been designed with a group of global food industry players, namely Barry Callebaut, Danone, Mars, Mondelez International, Nestlé and PepsiCo, and may welcome new partners.
In this model, stakeholder data is aggregated, then combined with other relevant public data, to provide anonymized consolidated information to support business-critical decision-making.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows:
- medical applications (84.4%): in industry, microbiological testing of samples from finished products, materials during the manufacturing process, or the environment, primarily in the food-processing, pharmaceutical, and cosmetics sectors;
- industrial applications (15.6%).
The group's diagnostic systems consist of three elements with related services: reagents, instruments (or platforms or analyzers), software, and services.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (32.4%), North America (44.1), Asia/Pacific (17.3%) and Latin America (6.2%).
BIOMÉRIEUX 
